Yarrow Bioscience, Inc. Common Stock
YARW
38 hedge funds and large institutions have $11.5M invested in Yarrow Bioscience, Inc. Common Stock in 2025 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 15 increasing their positions, 7 reducing their positions, and 3 closing their positions.
133% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 3
114% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 7
12% more funds holding
Funds holding: 34 → 38 (+4)
0.02% less ownership
Funds ownership: 0.96% → 0.94% (-0.02%)
51% less capital invested
Capital invested by funds: $23.4M → $11.5M (-$12M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$1.57M |
| 2 |
ACA
Acorn Capital Advisors
New York
|
+$810K |
| 3 |
PSC
Patient Square Capital
Menlo Park,
California
|
+$633K |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
+$468K |
| 5 |
EAM
Exome Asset Management
New York
|
+$269K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$4.67M |
| 2 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$493K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$320K |
| 4 |
SSA
Schonfeld Strategic Advisors
New York
|
-$226K |
| 5 |
Jane Street
New York
|
-$68K |
YARW Hedge Fund Activity: Q1 2025 in Review
38 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Yarrow Bioscience, Inc. Common Stock (YARW) for Q1 2025, worth a combined $11.5M — down 51% from $23.4M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new YARW positions and 3 closed out — a net gain of 4 holders — while 15 added to existing stakes and 7 trimmed.
The largest buyer was DAFNA Capital Management, opening a new position worth an estimated $1.57M. The largest seller was Cormorant Asset Management, exiting entirely with an estimated $4.67M sold.
- 38 institutional investors held Yarrow Bioscience, Inc. Common Stock (YARW) as of Q1 2025, up from 34 in Q4 2024.
- Funds reported $11.5M of Yarrow Bioscience, Inc. Common Stock stock for Q1 2025, down 51% quarter-over-quarter.
- 7 funds opened new Yarrow Bioscience, Inc. Common Stock positions in Q1 2025 and 3 closed out, a net change of +4 holders.
- The largest Yarrow Bioscience, Inc. Common Stock buyer in Q1 2025 was DAFNA Capital Management, an estimated $1.57M added.
- The largest Yarrow Bioscience, Inc. Common Stock seller in Q1 2025 was Cormorant Asset Management, an estimated $4.67M sold.
Based on aggregated 13F filings for Q1 2025.